Authors

• Jung Yong Hong (ORCID: https://orcid.org/0000-0003-1363-9332)
• Adam M. Burgoyne (ORCID: https://orcid.org/0000-0002-4351-9940)
• Robin Kate Kelley (ORCID: https://orcid.org/0000-0002-1984-2430)
• Masatoshi Kudo (ORCID: https://orcid.org/0000-0002-4102-3474)
• Stephen L. Chan (ORCID: https://orcid.org/0000-0001-8998-5480)
• Donatella Marino (ORCID: https://orcid.org/0000-0001-6565-0870)
• Lorenza Rimassa (ORCID: https://orcid.org/0000-0001-9957-3615)
• Joycelyn Jie Xin Lee (ORCID: https://orcid.org/0000-0002-1070-6125)
• René Gerolami
• Bruno Sangro (ORCID: https://orcid.org/0000-0002-4177-6417)
• Qiao Li (ORCID: https://orcid.org/0000-0001-7137-004X)
• Jee Hyun Kim (ORCID: https://orcid.org/0000-0003-1336-3620)
• Hitomi Nakamura
• Peng Sun
• Dirk‐Thomas Waldschmidt
• Binh V. Pham
• Boris Baur

Institutions

• AstraZeneca (United Kingdom) (GB)
• Humanitas University (IT)
• Chinese University of Hong Kong (HK)
• University of California, San Francisco (US)
• Aix-Marseille Université (FR)
• UC San Diego Health System (US)
• Samsung Medical Center (KR)
• Seoul National University Bundang Hospital (KR)
• University of California San Diego (US)
• Assistance Publique Hôpitaux de Marseille (FR)
• Prince of Wales Hospital (CN)
• Centro de Investigación Biomédica en Red (ES)
• A. O. Ordine Mauriziano di Torino (IT)
• Clinica Universidad de Navarra (ES)
• National Cancer Centre Singapore (SG)
• Vietnam National Children's Hospital (VN)
• AstraZeneca (Canada) (CA)
• AstraZeneca (United States) (US)
• University Hospital Cologne (DE)
• IRCCS Humanitas Research Hospital (IT)
• UCSF Helen Diller Family Comprehensive Cancer Center (US)
• Sungkyunkwan University (KR)
• Kindai University (JP)

Publication Details

Journal

Liver Cancer

Published

2025-12-18

DOI

https://doi.org/10.1159/000549955

Primary Topic

Hepatocellular Carcinoma Treatment and Prognosis

Type

article

Field-Weighted Citation Impact

0.00

Funders

• AstraZeneca